443914-94-1

Basic information

• Product Name: 3,4,5-TRIFLUOROPHENACYL BROMIDE
• Synonyms: 3,4,5-TRIFLUOROPHENACYL BROMIDE;2-Bromo-3',4',5'-trifluoroacetophenone, 2-Bromo-1-(3,4,5-trifluorophenyl)ethan-1-one;2-bromo-1-(3,4,5-trifluorophenyl)ethanone
• CAS NO: 443914-94-1
• Molecular Formula: C8H4BrF3O
• Molecular Weight: 253.02
• Mol File: 443914-94-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,4,5-TRIFLUOROPHENACYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5-TRIFLUOROPHENACYL BROMIDE(443914-94-1)
• EPA Substance Registry System: 3,4,5-TRIFLUOROPHENACYL BROMIDE(443914-94-1)

Safety Data

• Hazard Codes: T
• Hazardous Substances Data: 443914-94-1(Hazardous Substances Data)

Upstream product

• 220141-73-1 1-(3,4,5-trifluorophenyl)ethanone 
• 138526-69-9 3,4,5-trifluoro-1-bromobenzene 
• 69739-34-0 t-butyldimethylsiyl triflate 

Relevant articles and documents

NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

Synthesis and photoelectric properties of IrIIIcomplexes using fluorobenzylimidazole[2,1-b]thiazole derivatives as primary ligands

3-Methyl-6-(3,5-difluorophenyl)imidazo[2,1-b]thiazole (mdfpit) and 3-methyl-6-(3,4,5-trifluorophenyl)imidazo[2,1-b]thiazole (mtfpit) were easily prepared from thiourea, acetone, and 3,5-difluorobenzoyl bromide or 3,4,5-trifluorobenzoyl bromide. These were used as primary ligands to synthesize twelve phosphorescent IrIIIcomplexes with picolinic acid (pic), isoquinoline-3-carboxylic acid (3-IQA), quinoline-2-carboxylic acid (2-QA), 2-(pyridin-2-yl)phenol (2-ylppy), 2-(2,4-difluorophenyl)pyridine (dfppy), and pyridine-2-sulfonic acid (2-sappy) as auxiliary ligands. Their structures, photoluminescence, and electrochemical properties were investigated. Upon introducing more fluorine atoms into the benzene ring of the primary ligand, the thermal stability, photoluminescence quantum yield (PLQY), LUMO energy level, and luminous efficiency of the resulting IrIIIcomplexes are significantly improved, and the photoluminescence emission spectra are blue-shifted. Their maximum emission wavelengths are present in the range of 517-618 nm, and the luminous colors span from the green to red light region. Using the synthesized IrIIIcomplexes as emitters, LED chips based on InGaN chip excitation were developed, which showed good performances. Among all LEDs, the PLQY of the (mtfpmt)2Ir(pic) based LED is 58.4%, and the luminous efficiency is as high as 17.11 lm W?1; the luminous efficiency of the (mdfpmt)2Ir(2-QA) based LED is 3.41 lm W?1with CIE coordinates of 0.60 and 0.38, which are very similar to the saturated standard red light emission. The results demonstrate the potential of the studied IrIIIcomplexes as candidates for LED materials.

BIS(3-PHENETHYLOXYPHENYL) DISULFIDE AND METHOD FOR PRODUCING THE SAME

PROBLEM TO BE SOLVED: To provide a disulfide derivative that is an intermediate allowing a substituted phenyl ether compound having pest controlling effect to be synthesized conveniently and efficiently and a method for producing the same. SOLUTION: The present invention provides a bis(3-phenethyloxyphenyl) disulfide derivative represented by formula (1) (X is H or a halogen atom; R1 and R2 are a halogen atom, or R1 and R2 together bond to one O or S to represent (=O) or (=S); Y1-Y3 are a halogen atom or a C1-4 haloalkyl group). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPO&INPIT